Success Metrics

Clinical Success Rate
89.9%

Based on 232 completed trials

Completion Rate
90%(232/258)
Active Trials
9(3%)
Results Posted
40%(92 trials)
Terminated
26(8%)

Phase Distribution

Ph phase_3
70
21%
Ph phase_1
74
23%
Ph early_phase_1
11
3%
Ph not_applicable
41
13%
Ph phase_2
65
20%
Ph phase_4
63
19%

Phase Distribution

85

Early Stage

65

Mid Stage

133

Late Stage

Phase Distribution324 total trials
Early Phase 1First-in-human
11(3.4%)
Phase 1Safety & dosage
74(22.8%)
Phase 2Efficacy & side effects
65(20.1%)
Phase 3Large-scale testing
70(21.6%)
Phase 4Post-market surveillance
63(19.4%)
N/ANon-phased studies
41(12.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.7%

232 of 274 finished

Non-Completion Rate

15.3%

42 ended early

Currently Active

9

trials recruiting

Total Trials

326

all time

Status Distribution
Active(12)
Completed(232)
Terminated(42)
Other(40)

Detailed Status

Completed232
unknown40
Terminated26
Withdrawn16
Recruiting7
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
326
Active
9
Success Rate
89.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 111 (3.4%)
Phase 174 (22.8%)
Phase 265 (20.1%)
Phase 370 (21.6%)
Phase 463 (19.4%)
N/A41 (12.7%)

Trials by Status

terminated268%
withdrawn165%
completed23271%
active_not_recruiting21%
recruiting72%
not_yet_recruiting31%
unknown4012%

Recent Activity

Clinical Trials (326)

Showing 20 of 326 trialsScroll for more
NCT07831369Phase 2

VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

Recruiting
NCT07823751Not Applicable

The Role of Bisphosphonate and Simvastatin Combination on Therapeutic Response in Breast Cancer With Bone Metastasis Via Dicckopf-1 Pathway

Completed
NCT02968810Phase 2

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

Completed
NCT05580250Phase 1

A Study of LY3526318 in Healthy Male Japanese Participants

Withdrawn
NCT07779642Phase 2

Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory Failure

Not Yet Recruiting
NCT07102979Not Applicable

Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

Terminated
NCT05771675Early Phase 1

Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis

Recruiting
NCT05464810Early Phase 1

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

Recruiting
NCT07625930Phase 2

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial

Not Yet Recruiting
NCT03929744Phase 1

A Study of LY3502970 in Healthy Participants

Completed
NCT07692620Not Applicable

Alveolar Ridge Splitting With Simvastatin/PRF Composite and Simultaneous Implant Placement

Completed
NCT06186622Phase 1

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

Completed
NCT04514029Early Phase 1

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

Active Not Recruiting
NCT00858637Phase 3

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

Completed
NCT02675309Phase 1

A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects

Completed
NCT02197234Phase 1

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

Completed
NCT03889795Phase 1

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

Active Not Recruiting
NCT06948747Phase 1

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

Completed
NCT06858332

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Recruiting
NCT03896217Phase 2

Simvastatin in Secondary Progressive Multiple Sclerosis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
326